Bio Rad Laboratories Inc
NYSE:BIO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
263.97
374.28
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Bio Rad Laboratories Inc
Bio Rad Laboratories Inc
Cash from Financing Activities
Bio Rad Laboratories Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bio Rad Laboratories Inc
NYSE:BIO
|
Cash from Financing Activities
-$393.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash from Financing Activities
-$4.6B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Danaher Corp
NYSE:DHR
|
Cash from Financing Activities
-$8.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-34%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash from Financing Activities
-$881.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-13%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash from Financing Activities
-$752m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-23%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash from Financing Activities
-$923m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
-18%
|
|
Bio Rad Laboratories Inc
Glance View
Bio-Rad Laboratories Inc. began its journey in 1952 and has since positioned itself as a formidable player in the life sciences and clinical diagnostics sectors. Founded by David and Alice Schwartz, the company thrived on the burgeoning interest in biological research, carving a niche by supplying essential products to scientists and healthcare professionals. With its headquarters in Hercules, California, Bio-Rad has continually developed a suite of innovative solutions that cater to both academic research and the intricate needs of clinical diagnostics, paving its way to becoming a global leader. Their operations are distinctly bifurcated: Life Science, which focuses on products for gene expression, protein purification, and food safety, and Clinical Diagnostics, offering tools for blood testing and diabetes monitoring. The core of Bio-Rad’s business model lies in its ability to design and manufacture advanced technological products that streamline laboratory processes, making research and diagnostics more efficient and reliable. The Life Science segment generates revenue by selling reagents, lab instruments, and software that facilitate various laboratory protocols and experiments, assisting scientists in their pursuit of breakthroughs in biotechnology and pharmaceutical development. Meanwhile, the Clinical Diagnostics segment garners earnings through the provision of innovative testing and analysis tools that enable accurate disease diagnosis, blood analysis, and quality control. Guided by a robust infrastructure of research and development, the company continuously adapts to the evolving demands of science and healthcare, maintaining its fiscal health while reinforcing its reputation as a trusted provider in the global market.
See Also
What is Bio Rad Laboratories Inc's Cash from Financing Activities?
Cash from Financing Activities
-393.2m
USD
Based on the financial report for Sep 30, 2024, Bio Rad Laboratories Inc's Cash from Financing Activities amounts to -393.2m USD.
What is Bio Rad Laboratories Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-43%
Over the last year, the Cash from Financing Activities growth was -26%. The average annual Cash from Financing Activities growth rates for Bio Rad Laboratories Inc have been 7% over the past three years , -43% over the past five years .
You don't have any saved screeners yet
